University of Vermont scientists have isolated high quality, plasma proteins that are used for diagnosis and treatment of diseases of the blood. Kenneth Mann, Ph.D., professor emeritus of biochemistry, and an international expert in the field of blood clotting, led the research that resulted in seven patents related to the diagnosis and study of functions that are critical in normal blood coagulation.
Among Mann’s most notable inventions is a synthetic “plasma” mixture that is made up of proteins and membranes, and is designed to provide a clearer understanding of the regulation of blood coagulation.
Adding to the university’s leadership in the fields of coagulation research and protein biochemistry are the groundbreaking discoveries of Richard Jenny, Ph.D., and his colleagues. Original funding for much of the work came from grants from the National Institutes of Health. Jenny, whose career in coagulation research spans 25 years, co-founded Haematologic Technologies Inc. (HTI), located in Essex Junction, Vt., along with four of his colleagues. The company specializes in the isolation and characterization of high quality proteins for in vitro research worldwide.
Jenny has helped guide HTI from its initial two-person startup operation to its current status as an internationally recognized company.
This story was originally published in 2007.
To see available technologies from research institutions, click here to visit the AUTM Innovation Marketplace.